The FDA Expands Addyi Approval: A Lifeline for Postmenopausal Women Struggling with Low Libido

As she sipped her morning coffee, Lisa McKenzie, a 54-year-old mother of three, reflected on the profound changes she had experienced throughout her menopause journey. “I never thought I’d struggle with intimacy,” she confessed, tracing her finger around the rim of her cup. “It’s more than just physical; it’s emotional and affects my whole sense of self.” For Lisa and countless postmenopausal women, a recently expanded approval from the U.S. Food and Drug Administration (FDA) for Addyi (flibanserin) offers a glimmer of hope. Introduced in 2015 for premenopausal women, Addyi has been greenlit for those under 65 who experience hypoactive sexual desire disorder (HSDD), a condition that plagues approximately 9% of postmenopausal women.

Understanding Addyi’s Mechanism

Addyi is a groundbreaking non-hormonal prescription medication manufactured by Sprout Pharmaceuticals. It aims to address the often-silent struggles of women facing diminished sexual desire. “Addyi works by altering neurotransmitter levels in the brain to help regulate mood and enhance sexual drive,” explained Dr. Susan Marie Pacana, an OB/GYN at Hackensack Meridian Jersey Shore University Medical Center. “This approval is monumental; it finally brings recognition to a problem that so many women face but feel reluctant to discuss.”

According to Dr. Prudence Hall, a Santa Monica-based OB/GYN, the medication can lead to increased dopamine and serotonin levels, which are crucial for enhancing not just libido but overall mood. “After a month on Addyi, many patients report a tangible improvement in their sexual desire,” she remarked.

Why This Approval Matters

The FDA’s decision brings Addyi’s potential benefits to a larger demographic, addressing a key gap in women’s health. “Historically, many women aged 50 to 60 have voiced their concerns about decreased libido,” remarked Dr. G. Thomas Ruiz, a board-certified OB/GYN at MemorialCare Orange Coast Medical Center. “With this approval, we now have a legitimate treatment option for those who have felt sidelined.”

• Approximately 40-55% of women experience low sexual desire during menopause.
• 9% of postmenopausal women have been diagnosed with HSDD.
• Addyi can now be prescribed to women under 65, offering a pathway to treatment.

The impact of low libido can be severe, influencing not only a woman’s intimate relationships but also her self-esteem and mental health. “Women often come to us feeling ashamed and frustrated,” Pacana added. “They worry they aren’t living up to their partners’ expectations.” The expanded approval is seen as a crucial step toward providing these women with a medically sanctioned solution, alongside the promise of insurance coverage.

Potential Side Effects and Considerations

Like any medication, Addyi comes with its own set of potential side effects. These may include dizziness, dry mouth, nausea, and fatigue, all of which can complicate its use. Ruiz emphasized the importance of patient education: “A simple handout outlining the do’s and don’ts of using Addyi would be invaluable for both patients and providers.”

Given that the medication enhances neurotransmitter levels, some women might initially experience adverse effects. Lucille Thompson, a 57-year-old woman who trialed Addyi, shared, “The dizziness was a challenge at first, but the increase in desire made it worthwhile.”

Holistic Alternatives to Consider

For those wary of medications, Hall recommends exploring non-pharmaceutical options. “Optimizing hormones like estradiol can significantly improve not just sexual desire but overall quality of life,” she said. She often suggests treatments using estradiol patches or compounded creams combined with testosterone replacement. “For many women, this can lead to a renaissance of passion,” Hall added.

Moreover, Ruiz highlighted the need for women to deepen their understanding of their own sexual response. “Many women may benefit from learning about spontaneous versus responsive desire,” he explained. “Understanding that arousal can take time may help reduce anxiety around intimacy.”

Enhancing Intimacy: Techniques and Communication

Experts also suggest practical steps women can take to revive their sexual interest. Scheduling time for intimacy might seem unromantic, but it can be effective. “Foreplay doesn’t have to start in the bedroom,” Ruiz noted. “It can be an all-day affair. Establishing a positive emotional environment is crucial.”

Furthermore, Hall encourages self-exploration as a path to greater intimacy. “Understanding your body and learning what you enjoy can dramatically enhance your sexual experience and improve communication with your partner.”

For Lisa, the approval of Addyi couldn’t come soon enough. “I want to feel like myself again, to have that spark,” she said. “This could be a turning point, not just for me but for so many women like me.” With the winds of change swirling around women’s health, Addyi’s expanded indication offers hope for a renewed intimacy and empowerment for those who thought they had lost it forever.

Source: www.medicalnewstoday.com